Scolaris Content Display Scolaris Content Display

Psicoterapia individual en el tratamiento ambulatorio de adultos con anorexia nerviosa

Esta versión no es la más reciente

Contraer todo Desplegar todo

Referencias

Referencias de los estudios incluidos en esta revisión

Bachar 1999 {published data only}

Bachar E, Latzer Y, Kreitler S, Berry EM. Empirical comparison of two psychological therapies. Self psychology and cognitive orientation in the treatment of anorexia and bulimia. Journal of Psychotherapy Practice and Research 1999;8(2):115‐28.

Bergh 2002 {published data only}

Bergh C, Brodin U, Lindberg G, Sodersten P. Randomized controlled trial of a treatment for anorexia and bulimia nervosa. Proceedings of the National Academy of Sciences of the USA 2002;99(14):9486‐91.

Channon 1989 {published data only}

Channon S, de Silva P, Hemsley D, Perkins R. A contolled trial of cognitive‐behavioural and behavioural treatment of anorexia nervosa. Behavior Research and Therapy 1989;27(5):529‐35.

Dare 2001 {published data only}

Dare C, Eisler I, Russell G, Treaure J, Dodge L. Psychological therapies for adults with anorexia nervosa. British Journal of Psychiatry 2001;178:216‐21.

McIntosh 2005 {published data only}

Mcintosh VVW, Jordan J, Carter F, Luty SE, McKenzie JM, Bulik CMM, et al. Three psychotherapies for anorexia nervosa: a randomized controlled trial. American Journal of Psychiatry 2005;2005(162):4.

Serfaty 1999 {published data only}

Serfaty MA, Turkington D, Heap M, Ledsham L, Jolley E. Cognitive therapy versus dietary counselling in the outpatient treatment of anorexia nervosa: Effect of the treatment phase. European Eating Disoders Review 1999;7:334‐50.

Treasure 1995 {published data only}

Treasure J, Todd G, Brolly M, Tiller J, Nehmed A, Denman F. A pillot study of a randomized trial of cognitive analytical therapy vs educational behavioural therapy for adult anorexia nervosa. Behavior Research and Therapy 1995;33(4):363‐7.

Referencias de los estudios excluidos de esta revisión

Andrewes 1996 {published data only}

Andrewes DG, O'Connor P, Mulder C, McLennan J, Derham H, Weigall S, et al. Computerised Psychoeducation for Patients with Eating Disorders. Australian and New Zealand Journal of Psychiatry 1996;30:492‐7.

Attia 1998 {published data only}

Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa. American Journal of Psychiatry 1998;155(4):548‐51.

Ball 2004 {published data only}

Ball J, Mitchell P. A randomized controlled study of cognitive behavior therapy and behavioral family therapy for anorexia nervosa patients. Eating Disorders: The Journal of Treatment and Prevention 2004;12:303‐14.

Bhanji 1980 {published data only}

Bhanji S. Anorexia nervosa: two schools of thought. Nursing Times 1980;76:323‐4.

Biederman 1985 {published data only}

Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: A double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology 1985;5(1):10‐6.

Birmingham 1994 {published data only}

Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. International Journal of Eating Disorders 1994;15(3):251‐5.

Brambilla 2007 {published data only}

Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anoxia nervosa: psychobiological effects. International Clinical Psychopharmacology 2007;22:197‐204.

Brambilla 1995 a {published data only}

Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive‐behavioral, pschopharmacological and nutritional therapy in eating disorders: Anorexia nervosa restricted type. Biological Psychiatry 1995;32:59‐63.

Brambilla 1995 b {published data only}

Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive‐behavioral, pschopharmacological and nutritional therapy in eating disorders: Anorexia nervosa binge‐eating/purging type. Biological Psychiatry 1995;32:64‐7.

Casper 1987 {published data only}

Casper RC, Schlemmer RF, Javaid JI. A placebo‐controlled crossover study of oral clonidine in acute anorexia aervosa. Psychiatry Research 1987;20:249‐60.

Crisp 1987 {published data only}

Crisp AH, Lacey JH, Crutcherfield M. Clomipramine and drive in people with anorexia nervosa: An In‐patient study. British Journal of Psychiatry 1987;150:355‐8.

Crisp 1991 {published data only}

Crisp AH, Norton K, Gowers S, Halek C, Bowyer C, Yeldham D, et al. A controlled study of the effect of therapies aimed at adolescent and family psychopathology in anorexia nervosa. British Journal of Psychiatry 1991;159:325‐33.

Eckert 1979 {published data only}

Eckert ED, Goldberg SC, Halmi KA, Casper RC, Davis JM. Behaviour therapy in anorexia nervosa. British Journal of Psychiatry 1979;134:55‐9.

Eisler 1997 {published data only}

Eisler I, Dare C, Russell GF, Szmukler G, Le Grange D, Dodge E. Family and individual therapy in anorexia nervosa; A 5‐year follow‐up. Archives of General Psychiatry 1997;54:1025‐30.

Eisler 2000 {published data only}

Eisler I, Dare C, Hodes M, Russell G, Dodge E, Le Grange D. Family therapy for adolescent anorexia nervosa: The results of a controlled comparison of two family interventions. Journal of Child Psychology and Psychiatry 2000;41(6):727‐36.

Freeman 1992 {published data only}

Freeman C. Day patient treatment for anorexia nervosa. British Review of Bulimia and Anorexia Nervosa 1992;6(1):3‐8.

Garfinkel 1977 {published data only}

Garfinkel PE, Garner D, Moldofsky H. The role od Behavior Modification in the Treatment of Anorexia Nervosa. Journal of Pediatric Psychology 1977;2:113‐21.

Geist 2000 {published data only}

Geist R, Heinmaa M, Stephens D, Davis R, Katzman DK. Comparison of family therapy and family group psychoeducation in adolescents with anorexia nervosa. Canadian Journal of Psychiatry 2000;45:173‐8.

Goldberg 1979 {published data only}

Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in anorexia nervosa. British Journal of Psychiatry 1979;134:67‐70.

Goldberg 1980 {published data only}

Goldberg SC, Casper RC, Eckert ED. Effects of cyproheptadine in anorexia nervosa. Psychopharmacology Bulletin 1980;16(2):29‐30.

Gordon 1999 {published data only}

Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH, Leboff MS. Changes in bone turnover markers and menstrual function after short‐term oral DHEA in young women with anorexia nervosa. Journal of Bone and Mineral Research 1999;14:136‐45.

Gowers 1994 {published data only}

Gowers S, Norton K, Halek C, Crisp AH. Outcome of outpatient psychotherapy in a random allocation treatment study of anorexia nervosa. International Journal of Eating Disorders 1994;15(2):165‐77.

Grinspoon 1996 {published data only}

Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short‐term recombinant human insulin‐like growth factor I Administration on bone turnover in osteopenic women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1996;81:3864‐70.

Gross 1981 {published data only}

Gross HA, Ebert MH, Faden VB, Goldberg SC, Nee LE, Kaye WH. A double‐blind controlled trial of lithium carbonate in primary anorexia nervosa. Journal of Clinical Psychopharmacology 1981;1(6):376‐81.

Gross 1983 {published data only}

Gross H, Ebert MH, Faden VB, Goldberg SC, Kaye WH, Caine ED, et al. A double‐blind trial of tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology 1983;3(3):165‐71.

Hall 1987 {published data only}

Hall A, Crisp AH. Brief psychotherapy in the treatment of anorexia nervosa outcome at one year. British Journal of Psychiatry 1987;151:185‐91.

Halmi 1975 {published and unpublished data}

Halmi KA, Powers P, Cunningham S. Treatment of anorexia nervosa with behavior modification. Effectiveness of formula feeding and isolation. Archives of General Psychiatry 1975;32:93‐6.

Halmi 1982 {published data only}

Halmi KA, Eckert E, Falk JR. Cyproheptadine for anorexia nervosa. Lancet 1982;1(8285):1357‐8.

Halmi 1986 {published data only}

Halmi KA, Eckert E, LaDu TJ, Cohen J. Anorexia nervosa: Treatment efficacy of cyproheptadine and amitriptyline. Archives of General Psychiatry 1986;43(2):177‐81.

Halmi 1998 {published data only}

Halmi K, Agras S, Mitchell J, Crow S. Fluoxetine and cognitive‐behavioral therapy for anorexia nervosa; A multi‐center treatment study. Proceedings of the 21st Collegium Internationale Neuro‐psychopharmacologicum. 1998.

Halmi 2005 {published data only}

Halmi KA, Agras WS, Crow S, Mitchell J, Wilson GT, Bryson SW, et al. Predictors of treatment acceptance and completion in anorexia nervosa. Archives of General Psychiatry 2005;62:776‐81.

Hill 2000 {published data only}

Hill K, Bucuvalas J, McClain C, Kryscio R, Martini RT, Alfaro MP, et al. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. Journal of Child and Adolescent Psychopharmacology 2000;10(1):3‐8.

Kaye 2001 {published data only}

Kaye WH, Weltzin TE, Hsu G, Sokol MS, Conaha CM, Plotnicov KH, et al. Double‐blind placebo‐controlled administration of fluoxetine in restricting and restricting‐purging type anorexia nervosa. Biological Psychiatry 2001;49:644‐52.

Kehrer 1975 {published data only}

Kehrer HE. Anorexia nervosa treated by behavior modification. Medizinische Klinik 1975;70:427‐32.

Klibanski 1995 {published data only}

Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1995;80:898‐904.

Kong 2005 {published data only}

Kong S. Day treatment programme for patients with eating disorders: randomized controlled trial. Journal of Advanced Nursing 2005;51:5‐14.

Lacey 1980 {published data only}

Lacey JH, Crisp AH. Hunger, food intake and weight: The impact of clomipramine on a refeeding anorexia nervosa population. Postgraduate Medical Journal 1980;56:79‐85.

Le Grange 1992 {published data only}

Le Grange D, Eisler I, Dare C, Russell GF. Evaluation of family treatmets in adolescent anorexia nervosa: A pilot study. International Journal of Eating Disorders 1992;12(4):347‐57.

Marazzi 1995 {published data only}

Marazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. International Clinical Psychopharmacology 1995;10:163‐72.

Munford 1984 {published data only}

Munford PR, Tarlow G, Gerner R. Single case study: An experimental analysis of the interaction of chemotherapy and behaviour therapy in anorexia nervosa. Journal of Nervous and Mental Disease 1984;172(4):228‐31.

Pike 2003 {published data only}

Pike KM, Walsh BT, Vitousek K, Wilson GT, Bauer J. Cognitive behavior therapy in the posthospitalization treatment of anorexia nervosa. American Journal of Psychiatry 2003;160:2046‐9.

Pillay 1981 {published data only}

Pillay M, Crisp AH. The impact of social skills training within an established in‐patient treatment programme for anorexia nervosa. British Journal of Psychiatry 1981;139:533‐9.

Redmond 1976 {published data only}

Redmond DE, Swann A, Heninger GR. Phenoxybenzamine in anorexia nervosa. Lancet 1976;308:307.

Robin 1994 {published data only}

Robin AL, Siegel PT, Koepke T, Moye AW, Tice S. Family therapy versus individual therapy for adolescent females with anorexia nervosa. Developmental and Behavioral Pediatrics 1994;15:111‐6.

Robin 1999 {published data only}

Robin AL, Siegel PT, Moye AW, Gilroy M, Dennis AB, Sikand A. A controlled comparison of family versus individual therapy for adolescents with anorexia nervosa. Journal of the Americal Academy of Child and Adolescent Psychiatry 1999;38(12):1482‐9.

Russell 1987 {published data only}

Russell GF, Szmukler GI, Dare C, Eisler I. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Archives of General Psychiatry 1987;44:1047‐56.

Schmidt 1997 {published and unpublished data}

Schmidt U. Behavioural, cognitive‐behavioural, and cognitive‐analytical methods in the treatment of anorexia nervosa. Psychotherapie Psychosomatik Medizinische Psychologie 1997;47:316‐21.

Silbert 1971 {published data only}

Silbert MV. The weight gain effect of periactin in anorexic patients. South African Medical Journal 1971;45(14):374‐80.

Stacher 1993 {published data only}

Stacher G, Abatzi‐Wenzel TA, Wiesnagrotzki S, Bergmann H, Schneider C, Gaupmann G. Gastric emptying, body weight and symptoms in primary aneroxia nervosa: Long‐term effects of cisapride. British Journal of Psychiatry 1993;162:398‐402.

Szmukler 1985 {published data only}

Szmukler GI, Eisler I, Russell GFM, Dare C. Anorexia nervosa, parental expressed emotion and dropping out treatment. British Journal of Psychiatry 1985;147:265‐71.

Thien 2000 {published data only}

Thien V, Thomas A, Markin D, Birmingham CL. Pilot study of a graded exercise program for the treatment of anorexia nervosa. International Journal of Eating Disorders 2000;28:101‐6.

Vandereycken 1977 {published data only}

Vandereycken W, Pierloot R. Anorexia nervosa: weight recovery with behaviour therapy. Feuillets Pscyhiatrique de Liege 1977;10:47‐58.

Vandereycken 1982 {published data only}

Vandereycken W, Pierloot R. Pimozide combined with behaviour therapy in the short‐term treatment of anorexia aervosa: A double‐blind placebo‐controlled crossover study. Acta Psychiatrica Scandinavica 1982;66:445‐50.

Vandereycken 1984 {published data only}

Vandereycken W. Neuroleptics in the short‐term treatment of anorexia nervosa: A double‐blind placebo‐controlled study with sulpiride. British Journal of Psychiatry 1984;144:288‐92.

Weizman 1985 {published data only}

Weizman A, Tyano S, Wijsenbeek H, Ben David M. Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychotherapy and Psychosomatics 1985;43:136‐40.

Wulliemier 1975 {published data only}

Wullieimier F, Sinclair K, Rossel F. Behaviour therapy of anorexia nervosa. Journal of Psychosomatic Research 1975;19:267‐272.

Wulliemier 1982 {published data only}

Wulliemier F, Gaillard M. Comparative follow up study of treatments of anorexia nervosa (classical apprach and behavioural therapy). Journal of Psychosomatic Research 1982;36:113‐21.

Zhang 1994 {published data only}

Zhang YL, He L. Cognition behavior therapy of anorexia nervosa. Chung‐Hua Hu Li Tsa Chih 1994;29:80‐2.

Referencias adicionales

Aalto‐Setala 2001

Aalto‐Setala T, Martunnen M, Tuulio‐Henriksson A, Poilolainen K, Lonnqvist J. One‐month prevalence of depression and other DSM‐IV disorders among young adults. Psychological Medicine 2001;31:791‐801.

APA 1994

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. American Psychiatric Association, 1994.

Bruch 1973

Bruch H. Eating disorders: Obesity, anorexia nervosa and the person within. New York, NY: Basic Books, 1973.

Crisp 1992

Crisp AH, Callender JS, Halek C, Hsu LK. Long‐term mortality in anorexia nervosa. A 20‐year follow‐up of the St George's and Aberdeen cohorts. British Journal of Psychiatry 1992;161:104‐7.

Dare 1995

Dare C, Crowther C. Psychodynamic models of eating disorders. In: Szmulker G, Dare C, Treasure J editor(s). Handbook of Eating Dsiorders: Theory, treatment and research. Chichester: John Wiley & Sons, 1995:125‐139.

Dolan 1994

Dolan B. Gitzinger I. Why women? Gender isues and eating disorders. London: The Athlone Press, 1994.

Fairburn 1991

Fairburn CG, Jones R, Peveler RC, Carr SJ, Soloman RA, Burton J ET AL. Three psychological treatments for bulimia nervosa: A comparative trial. Archives of General Psychiatry 1991;48:456‐63.

Fairburn 1999

Fairburn CG, Shafran R, Cooper Z. A cognitive behavioural theroy of anorexia nervosa. Behavior Research and Therapy 1999;37:1‐13.

Fairburn 1999a

Fairburn CG, Cowen PJ, Harrison PJ. Twin studies and the etiology of eating disorders. International Journal of Eating Disorders 1999;26:349‐58.

Fairburn 1999b

Fairburn CG, Cooper Z, Doll HA, Welch SL. Risk factors for anorexia nervosa: three integrated case‐control comparisons. Archives of General Psychiatry 1999;56:468‐76.

Fairburn 2003

Fairburn CG, Cooper Z, Shafran R. Cognitive behaviour therapy for eating disorders: a "transdiagnostic" theory and treatment. Behaviour Research and Therapy 2003;41:509‐28.

Garner 1997 a

Garner DM, Needleman LD. Sequencing and integration of treatments. In: Garner DM, Garfinkel PE editor(s). Handbook of treatment for eating disorders. 2nd Edition. New York, NY: The Guilford Press, 1997:50‐66.

Garner 1997 b

Garner DM Garfinkel PE. Handbook of treatment for eating disorders. 2. New York, NY: The Guilford Press, 1997.

Garner 1997 c

Garner DM, Vitousek KM, Pike KM. Cognitive‐behavioural therapy for anorexia nervosa. In: Garner DM, Garfinkel PE editor(s). Handbook of treatments for Eating Disorders. 2nd Edition. New York, NY: The Guilford Press, 1997:67‐93.

Goodsitt 1997

Goodsitt A. Eating Disorders: A self‐psychological perspective. In: Garner DM, Garfinkel PE editor(s). Handbook of Treatments for Eating Disorders. 2nd Edition. New York, NY: The Guilford Press, 1997:205‐228.

Gull 1874

Gull WW. Anorexia nervosa (apepsia hysterica, anorexia hysterica). Transactions of the Clinical Society of London 1874;7:22‐8.

Herzog 1997

Herzog W, Deter H‐C, Fiehn W, Petzold E. Medical findings and predictors of long‐term physical outcome in anorexia nervosa: a prospective, 12‐year follow‐up study. Psychological Medicine 1997;27:269‐79.

Hoek 2003

Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. International Journal of Eating Disorders 2003;34:383‐96.

Hudson 2007

Hudson JI, Pope HG, Kessler RC. The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication. Biological Psychiatry 2007;61:348‐58.

Karwautz 2001

Karwautz A, Rabe‐Hesketh S, Hu X, Zhao J, Sham P, Collier DA, et al. Individual‐specific risk factors for anoreia nervosa: a pilot study using a discordant sister‐pair design. Psychological Medicine 2001;31:317‐29.

Katzman 1997

Katzman MA, Lee S. Beyond body image: The integratin of feminist and transcultural theories in the understanding of self‐starvation. International Journal of Eating Disorders 1997;22:385‐94.

Lasegue 1873

Lasegue C. On hysterical anorexia [De l'anorexie hysterique]. Archives Generales de Medicine 1873;i:385‐403.

Lucas 1991

Lucan AR, Beard CM, O'Fallon WM, Kurland LT. 50‐year trends in the incidence of anorexia nervosa in Rochester, Minn.: A population based study. American Journal of Psychiatry 1991;148:917‐22.

Meads 1999

Meads C, Gold L, Burls A, Jobanputra P. In‐patient versus out‐patient care for eating disorders. DPHE Report no 17 University of Birmingham1999. [ISBN 0704421151]

Moncrieff 2001

Moncrieff J, Churchill R, Drummond C, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10:126‐33.

Morgan 1975

Morgan HG, Russell GF. Value of family background and clinical features as predictors of longterm outcome in anorexia nervosa: Four year follow‐up study of 41 patients. Psychological Medicine 1975;5:355‐71.

Morgan 1988

Morgan HG, Hayward AE. Clinical assessment of anorexia nervosa. The Morgan‐Russell assessment schedule. British Journal of Psychiatry 1988;152:367‐71.

Pawluck 1998

Pawluck DE, Gorey KM. Secular trends in the incidence of anorexia nervosa: Integrative review of population‐based studies. International Journal of Eating Disordes 1998;23:347‐52.

PFCG 2001

The Price Foundation Collaborative Group. Deriving behavioural phenotypes in an international multi‐centre study of eating disorders. Psychological Medicine 2001;31:635‐45.

Prochaska 1992

Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors. American Journal of Psychology 1992;47:1102‐14.

RANZCP 2001

:Thornton C, Paxton S, Austin S, Ball J, Hamilton A, Reiger E, et al. Clinical practice guidelines for the psychological treatment of anorexia nervosa. www.ranzcp.org/cpg2001.

Russell 1970

Russell GF. Anorexia nervosa: its identity as an illness and its treatment. In: Price JH editor(s). Modern Trends in Psychological Medicine. Vol. 2, London: Butterworth, 1970:131‐164.

Striegel‐Moore 1995

Striegel‐Moore RH. A feminist perspective on the etiology of eating disorders. In: Brownell KD, Fairburn CG editor(s). Eating Disorder and Obesity. A comprehensive handbook. New York, NY: The Guilford Press, 1995:224‐229.

Treasure 2002

Treasure J, Schmidt U. Anorexia nervosa. Clinical Evidence 2002;6:705‐14.

Verhulst 1997

Verhulst FC, vzn der Ende J, Ferdinand RF, Kasius M. The prevalence of DSM‐III‐R diagnoses in a national sample of Dutch adolescents. Archives of General Psychiatry 1997;54:329‐36.

Vitousek 1998

Vitousek KM, Watson S, Wilson GT. Enhancing motivation for change in treatment resistant eating disorders. Clinical Psychology Review 1998;18:391‐420.

Wade 2000

Wade TD, Bulik CM, Neale M, et al. Kendler KS. Anorexia nervosa and major depression: shared genetic and environmental factors. American Journal of Psychiatry 2000;157:469‐471.

Ward 1996

Ward A, Troop N, Todd G, Treasure J. To change or not to change ‐ 'How' is the question?. British Journal of Medical Psychology 1996;69:139‐46.

WHO 1992

World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization, 1992.

Windauer 1993

Windauer U, Lennerts W, Talbot P, Touyz SW. How well are "cured" anorexia nervosa patients? An investigation of 16 weight‐recovered anorexic patients. British Journal of Psychiatry 1993;163:195‐200.

Wooley 1995

Wooley SC. Feminist influences on the treatment of eating disorders. In: Brownell KD, Fairburn CG editor(s). Eating Disorders and Obesity A comprehensive handbook. New York, ny: The Guilford Press, 1995:294‐298.

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Bachar 1999

Methods

Randomized controlled trial (RCT), duration of treatment was for a year, followed by one year of follow‐up. Treatment integrity was done by written or recorded sessions, blinding of outcome evaluation was unclear, ITT was not included.

Participants

13 female patients with anorexia nervosa (DSM‐IV)
Mean age 18.1 years (SD 2.4). 5% of those screened were excluded.

Interventions

Self psychological treatment vs cognitive orientation. Both groups had nutritional counselling.

Outcomes

DSM Symptomatology Scare, Eating Attitudes Test (EAT 26), Global Severity Index (GSI) and Selves Questionnaire

Notes

Blinding of the outcome unclear, allocation of concealment not mentioned and specific outcome data was not avalable for anorexia nervosa participants.

Sequence Genereation: The bulimia group was divided into the control, self psychotherapy and cognitive orientation therapy groups, and the anorexia group was divided into the COT and SPT group such that both intervention groups had 17 people and the control group had 10 people: "The 31 bulimic patients were randomly assigned to the three groups in the following numbers: 10 in SPT, 11 in COT, and 10 in C/NC. The 13 anorexic patients were randomly assigned to the two psychological treatment groups: 7 in SPT and 6 in COT. Thus, the total number of patients in each group at the beginning of this study was 17 in SPT, 17 in COT, and 10 in C/NC." ‐ allocation sequence was adequately generated.

Incomplete Outcome Data: Specific outcome data was not made available for anorexia (only mentioned for bulimia). There was no explanation given as to why. Numbers were given for drop‐outs, but no explanations: "Finally, one of the inherent problems with treatment studies is dropout. We know that the dropouts in the present study did not differ on any of the sociodemographic data or on the baseline of any of the outcome measures. But we do not know whether they have gone elsewhere for therapy or whether they differed on a crucial and yet unquantifiable measure of willingness to be cured. The dropout rate in our sample was 25%." ‐ incomplete outcome data was not completely addressed.

Selective Outcome Reporting: Considerable attrition of data, no explanations given for drop‐outs. There was also no ITT. Also, as mentioned previously, specific outcome data was omitted for anorexia.There was no reporting of potential conflicts of interest: "We did not implement an intent‐to‐treat analysis because the dropouts in our study left within the first few sessions of the therapy, which lasted one year." There was also bias in the selection stradegy in that subjects were "from families belonging to the upper middle class" even though "The target population for this study consisted of all the bulimic and anorexic patients who were referred to the eating disorder units of the psychiatry departments of two general hospitals in Israel" (at least mentions the area from which subjects were selected. There were no inclusion and exclusion criteria for subjects detailed in this paper ‐ the lack of ITT in particular is indicative of selective outcome reporting. Also, the attrition of anorexia data could be indicative of this.

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B ‐ Unclear

Bergh 2002

Methods

RCT of a treatment for 19 anorexia nervosa and 13 bulimia nervosa patients. Randomization by computer generation and allocations were kept in sealed envelopes. No comparative data of treatment outcome is presented for active and control groups in the published paper but this was supplied later by the authors. Cisapride was administered to seven anorexia nervosa patients. Four patients were treated as inpatients for between 8 and 30 days. It was unclear if outcome ratings were blind to group status.

Participants

19 patients with anorexia nervosa (DSM‐IV). Median age was 16 (range 10‐33). 19 of 47 screened (40%) participated.

Interventions

The treatment incorporated computer supported feedback to participants on satiety ratings. The approach was predomiantly nutritional and behavioural.Controls were placed on a wait‐list of variable duration (7.1‐21.6 months).

Outcomes

Remission (defined as no longer meeting criteria for an eating disorder). Body weight, psychiatric profile and laboratory tests were normal. Patients had to state food and dieting were no longer problems and they were back in school or professional activites.

Notes

Data as to the numbers of anorexia nervosa patients assigned to active treatment and control groups (10 and 8 respectively) was provided by the authors.

Sequence Generation: "We used a computer‐generated randomization list to assign patients to treatment or deferred treatment. Randomization was done in blocks of four consecutive patients at the time of the initial evaluation." ‐ the allocation sequence was adequately generated.

Allocation concealment: "Treatment allocations were kept in numbered sealed envelopes." ‐ allocation was adequately concealed.

Blinding: It was unclear if outcome ratings were blind to group status. ‐ Treatment allocation was adequately blinded but it was unclear whether outcome ratings were blind to group status.

Incomplete Outcome Data: No comparative data of traetment outcome is presented for active and control groups in the published paper: There was very little detail presented in this regard; only a graph comparing the control to the active treatment group only in terms of percentage of group in remission. ‐ incomplete outcome data was not adequately addressed.

Selective Outcome Reporting: Authors did not give comprehensive details on the selection strategy of subjects (specifically the area from which they were picked). Inclusion criteria was given as a reference to the Diagnostic and Statistical Manual of Mental Disorders(DSM)‐IV). No comparative data of traetment outcome is presented for active and control groups in the published paper: There was very little detail presented in this regard; only a graph comparing the control to the active treatment group only in terms of percentage of group in remission: ‐ it is possible that there was selective outcome reporting.

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A ‐ Adequate

Channon 1989

Methods

Randomized controlled trial (RCT), duration of treatment was 6 months and follow‐up was one year. All treatment sessions were audiotaped, outcome evaluation was not blind, ITT by withdrawals followed up and included in analysis.

Participants

24 female patients with anorexia nervosa (Russell's 1983 criteria) Mean age 23.84 years. 29% of those screened were excluded.

Interventions

Cognitive behavioural therapy vs behavioural therapy vs specialist eclectic therapy.

Outcomes

BMI, Morgan and Russell interview and Self report measures of Eating Disorders Inventory (EDI), Beck Depression Inventory (BDI), Maudsley Obsessive‐ Compulsive Inventory and preferred weight.

Notes

Sequence allocation: "Restricted randomisation was made in blocks of six, so that equal numbers of Ss were entered into each group after every six referrals." The sequence allocation was not adequately described.

Blinding: Outcome evaluation was not blind. No mention of any other blinding.

Incomplete Outcome Data: "There were no dropouts in the cognitive‐behavioural group. One subject in the behavioural group and two in the control treatment dropped out during the 12‐month follow‐up period, but were seen at the appropriate assessment intervals and included in the analysis." There was no reason given for this drop‐out. ITT by withdrawals followed up and included in analysis (information given by authors on request). Incomplete outcome data was adequately addressed.

Selective Outcome Reporting: Authors gave sufficient detail on where patients came from and the inclusion criteria for subjects in this study which reducing the risk of selective outcome reporting. "The Ss were a series of female outpatients from the Eating Disorders Clinic of the Maudsley Hospital, London, who were referred for the trial during the 15month intake period, and who met Russell's (1983) diagnostic criteria for anorexia nervosa. Patients with bulimic features were accepted only if they also met the diagnostic criteria for anorexia nervosa. There was no selection for the amount of treatment received prior to acceptance into the trial. Thirty‐four patients were referred for an initial assessment, and 24 of these met the admission criteria for the trial."
Transparency about sources of support (reduces risk of bias). "Acknowledgements‐The authors wish to express their gratitude to Professor Gerald Russell, in whose unit this study was carried out for his help and encouragement; and the Bethlem‐Maudsley Research Fund. for a generous grant that supported the study."
There is a very small risk of selective outcome reporting in this study.

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B ‐ Unclear

Dare 2001

Methods

Randomized controlled trial (RCT), duration of treatment was for a year, no follow‐up reported beyond this, treatment was closely supervised but integrity not formally assessed, outcome evaluation was not blind, ITT by estimation of outcome.

Participants

84 (two men) with anorexia nervosa (DSM‐IV) Mean age 26.3 years and all >18 years.

Interventions

Focal psychoanalytic psychotherapy (1 year) vs cognitive analytic therapy (7 months) vs Family therapy (1 year) vs routine treatment (1 year). 'Routine treatment' was a low‐contact management, the usual practice of an eating disorder service in which specialist treatments are not used. Therapist were mid‐level trainee psychiatrists who changed rotations each 6 months. Sessions were 30 minutes with weekly supervision over one year. Therapy included psycho‐education, supportive encouragement towards a more healthy diet, and regular monitoring of weight and physical state.

Outcomes

Morgan and Russell interview and BMI

Notes

The CAT was not 'purely' individual in that it included some contact between parents and/or the partner of the patient, and their relationship to the therapy and patient was a topic of treatment.

Sequence generation: “A stratified randomization procedure – the minimization method (Pocock 1983) was used to control for the age of onset and the duration of the illness, the presence of bulimic symptoms and marital status.” ‐ allocation sequence was adequately generated.

Allocation concealment: no method of allocation concealment mentioned.

Blinding: Subjects were blinded to which treatment group they would join, but at follow up the patients experiences of therapy were explored at the end of the interview, so they were no longer blinded (outcome evaluation not blind).: “The initial assessment was blind to the treatment to which the patients would be allocated. At the follow up assessments, the patients’ experiences of therapy were explored at the end of the interview, and therefore the follow‐up research clinician was not blind to the treatment.” ‐ Blinding was performed to the extent it could have been since the follow up involved an interview discussion of the patient's experiences.

Incomplete outcome data: All outcomes were followed up for 1 year, but only 73% of patients at the beginning were followed‐up after one year (with telephone follow up for a further 11%). Researchers were transparent in their reporting of data, especially drop‐outs, but did not give explanations for drop‐outs. ITT reported by estimation of outcome. ‐ Outcome follow up was incomplete in spite of best efforts.

Selective outcome reporting: Authors were transparent about numbers but not explanations on drop‐outs. There were no reports of potential conflicts of interest. Authors were transparent about power of the study and were also transparent about inclusion and exclusion criteria for subjects (reducing potential for bias: this is written in the "Patients" subheading in the study). The area the patients came from was mentioned ("psychiatric teaching hospital, the Maudsley) ‐ It is possible but unlikely that there was selective outcome reporting.

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A ‐ Adequate

McIntosh 2005

Methods

Randomized controlled trial (RCT), duration of treatment was 20 sessions over a minumum of 20 weeks. Treatment integrity was done and sessions were recorded, blinding of outcome evaluation was done, ITT was included (by carrying forward the last observation). Randomisation was computer generated and sealed envelopes were used for allocation concealment. Follow‐up is ongoing at 3,6,9,12 months and 2,3,5 years post‐treatment.

Participants

56 female patients with anorexia nervosa (DSM‐IV criteria) of EDNOS AN (lenient weight BMI 17.5‐19, DSM‐IV criteria) without amenorrheoa criteria being imposed. Age 17‐40 years. 42% of those screened were excluded.

Interventions

Cognitive behaviour therapy vs interpersonal psychotherapy vs nonspecific clinical management.

Outcomes

Primary outcome: clinician global rating: 4=full criteria for spectrum AN, 3=number of features of AN but not full criteria, 2= few features of an eating disorder, 1= no significant features of eating disorders
Secondary outcomes: self‐report EDI‐2, height, weight, %body fat, EDE subscale scores, GAF (DSM‐IV), Hamilton Depression Rating Scale.

Notes

Moderately high exclusion rate: 400 inquiries, 135 individuals interviewed, 78 deemed eligible.
Treatment relatively short. Nonspecific therapy incorporated CBT elements such as psychoeducation and had focus on nromalising eating. Authors provided further information on design of study.

Sequence Generation: randomization was computer generated (wrote to author to find out). ‐ allocation sequnce was adequate.

Allocation concealment: envelopes were used for allocation concealment (wrote to author to find this out). ‐ Allocation concealment was sufficient.

Blinding: Blinding of outcome evaluation was done (found out from author). ‐ Knowledge of the allocated interventions were adequately prevented during the study.

Incomplete outcome data: Outcome data was complete for all subjects who completed the study. There were many few drop‐outs, but these all well explained and well accounted for, and ITT analysis was performed by carrying last observation forward. ‐ Incomplete outcome data was properly addressed with ITT and through accountability.

Selective outcome reporting: authors were transparent about potential sources of support (therefore reducing sources of bias) (Supported by project (97/144) and program grants from the Health Research Council of New Zealand.) Furthermore there was a considerably high exclusion rate of subjects, suggesting that there is the possibility of selecting subjects with biased judgement. Authors were quite transparent about selection stradegy for patients: "The inclusion criteria for this study were female gender, an age of 17–40 years, and the presence of current primary anorexia nervosa; the participants included individuals diagnosed according to the DSM‐IV weight criterion (body mass index, <17.5), which was considered to be a strict definition of anorexia nervosa, andthose diagnosed according to a lenient weight criterion (body
mass index, 17.5–19.0) (20). Individuals with a body mass index below 14.5 were considered unsuitable for outpatient psychotherapy and were referred for assessment at an inpatient unit. In light of debate as to the necessity of amenorrhea in diagnosing anorexia nervosa (21), amenorrhea was not an inclusion requirement. The exclusion criteria were current severe major depression, psychoactive substance dependence, major medical or neurological illness, developmental learning disorder, cognitive impairment, bipolar I disorder, schizophrenia, or a chronic, refractory course of anorexia nervosa. Individuals receiving a stable dose of a psychotropic medication with no change in anorexia nervosa symptoms were included; however, only two individuals were taking an antidepressant medication. Recruitment was broad‐based and included referrals from health professionals, self‐referrals, and family referrals. The study received ethical approval from the Southern Regional Ethics Committee, and written informed consent was obtained." The area where the subjects came from was not mentioned.

Risk of bias ‐ low

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A ‐ Adequate

Serfaty 1999

Methods

Randomized controlled trial (RCT), duration of treatment was six months (20 weekly sessions) and no further follow‐up was reported, treatment integrity was assessed using audiotaped sessions, outcome evaluation was not blind, ITT by estimation of outcome.

Participants

35 (two men) with anorexia nervosa (DSM III‐R) over 16 years of age. None of those screened were excluded. Seven participants had a BMI of between 17.5 and 19 thus technically not meeting diagnostic criteria.

Interventions

Cognitive therapy vs dietary advice.

Outcomes

BMI, EDI, Dysfunctional Attitudes Scale(DAS), Locus of Control of Behaviour (LCB) and BDI

Notes

Sixth month data reported as "follow‐up" is presumed to be end of treatment data. Authors responded to inquiries.

Sequence Generation: “Using cards randomly placed into sealed envelopes, patients were allocated to one of two groups; dietician control (D) or cognitive therapy (CT).” ‐ Allocation sequence was sufficiently generated.

Allocation Concealment: Cards which allocated subjects to their random group were placed in envelopes (wrote to authors to get this information. ‐ Allocation was adequately concealed.

Blinding: Outcome evaluation was not blind, but personnel and participants were blinded for allocation (information received later from authors). During the study, knowledge of the allocated interventions were sufficiently concealed.

Incomplete outcome data: In the dietary counselling group, all subjects dropped out. ITT analysis by estimation of outcome was used for clinical diagnosis and BMI for this group. No further follow up was reported. Authors were transparent about numbers and explanations of drop‐outs: "All the patients in the dietary advice group had dropped out within 3 months of entry into the study.""Although follow‐up of the dietary control group was attempted, by writing and telephoning all participants and their GPs, the dietary control group refused to allow data to be released." ‐ Incomplete outcome data were not sufficiently addressed (could have been followed up by a phone call rather than ITT estimation analysis).

Selective Outcome Reporting: Authors were transparent about their selection of subjects strategy suggesting limited bias in outcome reporting:"Participants were drawn from a consecutive group of new patient general practitioner referrals to a new Eating Disorders Service at the Royal Hallamshire Hospital serving a catchment area of approximately 500,000. Although it is possible that a very small number of patients were referred to therapists in the private sector, this practice is extremely rare and there were no other NHS disposal routes for referrals." Inclusion criteria was mentioned: "All patients were eligible for the study, providing they were 16 years old or more and had a DSM‐III‐R (American Psychiatric Association, 1987) diagnosis of anorexia nervosa."
No follow up reported after the 6 months of treatment. Authors were transparent about numbers and explanations of drop‐outs (mentioned in incomplete outcome data). No report of potential conflicts of interest (potential source of bias). ‐ It is possible but unlikely that there has been selective outcome reporting.

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A ‐ Adequate

Treasure 1995

Methods

Randomized controlled trial (RCT), duration of treatment was 5 months with one year follow‐up, treatment integrity was not done, outcome of evaluation was not blind, ITT by withdrawals followed up and included in analysis

Participants

30 (one man) with anorexia nervosa (ICD‐10) All over 18 years in age. 21% of those screened were excluded.

Interventions

Educational Behavioural therapy (EDT) vs cognitive analytic therapy (CAT)

Outcomes

Morgan and Russell interview and BMI

Notes

End of Treatment data not reported. Authors responded to inquiries. They reported that the EBT group would be more like a "treatment as usual" than "dietary advice alone" treatment and the CAT was the same as in the Dare 2001 study.

Sequence Generation: Subjects were randomly number allocated to different treatment groups, but this was matched: “After assessment patients were randomised using random numbers to the two treatment groups, (1) educational behavioural therapy and (2) cognitive analytical therapy.= “The randomisation was successful in that the groups were well matched before treatment” ‐ Allocation generation was adequate.

Allocation Concealment: No mention of strategies of allocation concealment.

Blinding: Outcome evaluation was not blind. Apart from this, there was no other mention of the blinding stradegies ‐ Unclear as to blinding to personnel and participants was sufficient but outcome evaluation was not blinded.

Incomplete outcome data: Authors were transparent about drop‐out numbers and explanantions, but did not report use of ITT.: “Thirty eight patients were assessed and thirty two fulfilled these entry criteria. Of these one lost further weight after the assessment interview and was admitted before therapy began. One eligible patient refused the offer of treatment.”‐ Incomplete outcome data was properly explained, but unclear if it was accounted for (e.g. through ITT).

Selective Outcome Data: Transparency about short comings and potential conflicts of interest so unlikely to be selective reporting: “The size of the study was small and so the power to distinguish between two forms of treatment was limited. As this was a pilot study of a new approach the therapists were relatively inexperienced.” Authors gave sufficient details on the selection strategy of subjects including where they came from and also inclusion criteria: "The subjects were a consecutive series of outpatients from the Eating Disorder Clinic at the Maudsley Clinic who were referred for treatment during the eighteen month recruitment phase of the trial. All patients met ICD‐10 diagnosis for anorexia nervosa and were over 18 years in age. Patients with a mixed diagnosis of anorexia nervosa and bulimia nervosa were included (see Table 1 for details of how many binged or used the various weight control measures). Patients were excluded if the psychiatrist giving the assessment interview judged that inpatient treatment was necessary
because of extreme, rapid weight loss with additional symptoms and signs of severe emaciation such as proximal myopathy, marrow suppression or hypoglycaemia."‐ It is possible that the has been selective outcome reporting with the lack of detail given on drop‐outs (mentioned in the incomplete outcome data section).

Risk of bias ‐ present

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Unclear risk

B ‐ Unclear

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Andrewes 1996

RCT of computerised psychoeducation, which was not pertinent to the questions in this review.

Attia 1998

RCT of fluoxetine treatment, which was not pertinent to the questions in this review.

Ball 2004

An RCT of individual CBT versus family therapy, thereby not pertinent to his review but to the review of family therapy. (No differences between groups in this study were found however.)

Bhanji 1980

This is a typology study comparing different types of anorexia, not an intervention study.

Biederman 1985

RCT of amitriptyline versus placebo‐controlled study, which was not pertinent to the questions in this review.

Birmingham 1994

RCT of zinc treatment, which was not pertinent to the questions in this review.

Brambilla 2007

RCT of olanzapine therapy + cognitive behaviour therapy vs placebo + cognitive behavior therapy, which was not pertinent to the questions in this review.

Brambilla 1995 a

RCT of combined cognitive‐behavioural versus antidepressant drugs versus nutritional therapy, which was not pertinent to the questions in this review.

Brambilla 1995 b

RCT of combined cognitive‐behavioural versus antidepressant drugs versus nutritional therapy, which was not pertinent to the questions in this review.

Casper 1987

RCT of clonidine treatment, which was not pertinent to the questions in this review.

Crisp 1987

RCT of clomipramine treatment, which was not pertinent to the questions in this review.

Crisp 1991

RCT of individual and group (both including family therapy) versus inpatient treatment vs assessment only in adults >20 years, which was not pertinent to the questions in this review.

Eckert 1979

RCT of behavioural therapy, which was not pertinent to the questions in this review.

Eisler 1997

RCT of family therapy and individual therapy of 5 year follow‐up, which was not pertinent to the questions in this review.

Eisler 2000

RCT of two forms of family therapy, which was not pertinent to the questions in this review.

Freeman 1992

RCT of day patient programme, which was not pertinent to the questions in this review.

Garfinkel 1977

A review used to identify studies. Not an RCT.

Geist 2000

RCT of family therapy versus family group psychoeducation therapy, which was not pertinent to the questions in this review.

Goldberg 1979

RCT of cyproheptadine treatment, which was not pertinent to the questions in this review.

Goldberg 1980

RCT of cyproheptadine treatment , which was not pertinent to the questions in this review.

Gordon 1999

RCT of changes in bone turnover markers and menstrual function after short‐term oral DHEA, which was not pertinent to the questions in this review.

Gowers 1994

RCT of individual and family psychotherapy versus no treatment, which was not pertinent to the questions in this review.

Grinspoon 1996

RCT of human insulin‐like growth factor on bone turnover in osteopenic women with aneroxia nervosa, which was not pertinent to the questions this review.

Gross 1981

RCT of lithium carbonate treatment, which was not pertinent to the questions in this review.

Gross 1983

RCT of tetrahydrocannabinol treatment, which was not pertinent to the questions in this review.

Hall 1987

RCT of dietary advice versus combined individual and family psychotherapy, which was not pertinent to the questions in this review.

Halmi 1975

A trial investigating the effects of behaviour therapy; it did not meet the cirteria for this review because it was not an RCT and it did not compare behaviour therapy to any other interventions investigated in this review.

Halmi 1982

RCT of cyproheptadine treatment versus amitriptyline treatment, which was not pertinent to the questions in this review.

Halmi 1986

RCT of cyproheptadine treatment versus amitriptyline treatment, which was not pertinent to the questions in this review.

Halmi 1998

RCT comparing drug therapy (fluoxetine) to cognitive‐behavioural therapy, which is not a comparison pertinent in this review.

Halmi 2005

Study of predictors of treatment acceptance (primary treatment efficacy outcomes not reported) with only 37% completion rate. High self‐esteem was the single predictor of treatment completion. Non‐completion rates were highest in the medication alone (fluoxetine 60mg) group vs CBT vs combined treatment.

Hill 2000

RCT. Pilot study of recombinant human growth hormone treatment, which was not pertinent to the questions in this review.

Kaye 2001

RCT Fluoxetine treatment, which was not pertinent to the questions in this review.

Kehrer 1975

Not an RCT. Did not compare behaviour therapy to any other form of psychotherapy. Only 8 participants.

Klibanski 1995

RCT of estrogen therapy on trabecular bone loss in young women with aneroxia nervosa, which was not pertinent to the questions in this review.

Kong 2005

RCT of a comprehensive combined psychological (CBT and IPT) and pharmacological (SSRIs and benzodiazepines) delivered in a day versus an outpatient setting. An interesting study but not pertinent to the questions in this review.

Lacey 1980

RCT of clomipramine treatment, which was not pertinent to the questions in this review.

Le Grange 1992

RCT of conjoint family therapy versus family therapy, which was not pertinent to the questions in this review.

Marazzi 1995

RCT of naltrexone treatment, which was not pertinent to the questions in this review.

Munford 1984

Single case study of chemotherapy and behavioural therapy, which was not pertinent to the questions in this review.

Pike 2003

An interesting study of cognitive behaviour therapy following hospitalisation and weight gain to within 90% of ideal body weight., but thereby not pertinant to the questions in this review.

Pillay 1981

RCT of social skills training versus placebo condition, which was not pertinent to the questions in this review.

Redmond 1976

A letter detailing suggestions for future research into anorexia nervosa. Not an RCT.

Robin 1994

RCT of family therapy versus individual therapy, which was not pertinent to the questions in this review.

Robin 1999

RCT of family therapy versus individual therapy, which was not pertinent to the questions in this review.

Russell 1987

RCT of family therapy versus individual therapy, which was a study following weight restoration and therby not pertinent to the questions in this review.

Schmidt 1997

This paper describes the current state of the different psychotherapies and their application and suggests reasons why proper evaluations as to the gold standard treatment have not been made. Not an RCT.

Silbert 1971

RCT of periactin treatment, which was not relevant to the questions in this review.

Stacher 1993

RCT of Cisapride treatment, which was not relevant to the questions in this review.

Szmukler 1985

RCT of parental expressed emotion and dropping out treatment, which was not relevant to the questions in this review.

Thien 2000

RCT. Pilot study of a graded exercise program, which was not pertinent to the questions in this review.

Vandereycken 1977

RCT of CBT vs behavioural family therapy. It was excluded because this review focuses on individual psychotherapy, not family therapy.

Vandereycken 1982

RCT of pimozide combined with behavioural therapy, which was not pertinent to the questions in this review.

Vandereycken 1984

RCT of neuroleptics treatment, which was not pertinent to the questions in this review.

Weizman 1985

A trial (not randomized) investigating the efficacy of pimozide compared to behaviour therapy. Drug therapy was not a intervention investigated in this review; also, RCT were required for this review.

Wulliemier 1975

A trial (not randomized) investigating isolation, appetite stimulating drugs and psychotherapy against psychotherpay. It was not included because it is not RCT and one of the interventions included in this study was not of relevance for the review.

Wulliemier 1982

This is a retrospective comparative study comparing the "classic" approach (strict isolation, medication and psychotherapy) against the then contemporary method of conditioning and avoidance learning. Neither of these interventions were relevant to this review, and this trial was not randomised, therefore it was excluded.

Zhang 1994

Not an RCT. SImply examines the effects of just one type of psychotherapy (cognitive behaviour therapy) and does not compare psychotherapies.

Data and analyses

Open in table viewer
Comparison 1. CAT versus individual focal psychotherapy (FPT: Dare et al., 2001).

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end). Show forest plot

1

43

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.73, 1.62]

Analysis 1.2

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end)..

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end)..

3 N participants not completing treatment for any reason Show forest plot

1

43

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.47, 1.93]

Analysis 1.3

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 3 N participants not completing treatment for any reason.

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 3 N participants not completing treatment for any reason.

Open in table viewer
Comparison 2. FPT versus treatment as usual (Dare et al., 2001)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved". Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.51, 0.97]

Analysis 2.1

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved"..

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved"..

2 N participants not completing the treatment for any reason Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.23, 2.31]

Analysis 2.2

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the treatment for any reason.

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the treatment for any reason.

Open in table viewer
Comparison 3. CAT versus treatment as usual (Dare et al., 2001)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months Show forest plot

1

41

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.58, 1.01]

Analysis 3.1

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months.

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months.

2 N participants not completing the trial for any reason Show forest plot

1

41

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.56, 2.97]

Analysis 3.2

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the trial for any reason.

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the trial for any reason.

Open in table viewer
Comparison 4. Dietary advice versus cognitive therapy (Serfaty et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment for any reason Show forest plot

1

35

Risk Ratio (M‐H, Random, 95% CI)

0.10 [0.03, 0.33]

Analysis 4.1

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 1 N participants not completing treatment for any reason.

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 1 N participants not completing treatment for any reason.

2 Mean BMI at end of treatment Show forest plot

1

35

Std. Mean Difference (IV, Random, 95% CI)

0.71 [‐0.05, 1.46]

Analysis 4.2

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 2 Mean BMI at end of treatment.

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 2 Mean BMI at end of treatment.

Open in table viewer
Comparison 5. Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities. Show forest plot

1

19

Risk Ratio (M‐H, Random, 95% CI)

15.75 [1.06, 234.87]

Analysis 5.1

Comparison 5 Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control, Outcome 1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities..

Comparison 5 Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control, Outcome 1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities..

Open in table viewer
Comparison 6. Educational psychotherapy versus CAT (Treasure et al., 1995)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment for any reason Show forest plot

1

30

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.53, 1.45]

Analysis 6.1

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 1 N participants not completing treatment for any reason.

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 1 N participants not completing treatment for any reason.

2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up. Show forest plot

1

30

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.69, 2.11]

Analysis 6.2

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up..

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up..

3 Mean BMI at 12 months follow‐up Show forest plot

1

30

Std. Mean Difference (IV, Random, 95% CI)

‐0.41 [‐1.13, 0.32]

Analysis 6.3

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 3 Mean BMI at 12 months follow‐up.

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 3 Mean BMI at 12 months follow‐up.

4 Average Morgan & Russell scores at 12 months follow‐up Show forest plot

1

30

Std. Mean Difference (IV, Random, 95% CI)

‐0.32 [‐1.04, 0.40]

Analysis 6.4

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 4 Average Morgan & Russell scores at 12 months follow‐up.

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 4 Average Morgan & Russell scores at 12 months follow‐up.

Open in table viewer
Comparison 7. Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not having a good outcome (BMI > 17.5 and return of menstruation) Show forest plot

1

13

Risk Ratio (M‐H, Random, 95% CI)

0.34 [0.12, 0.96]

Analysis 7.1

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 1 N participants not having a good outcome (BMI > 17.5 and return of menstruation).

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 1 N participants not having a good outcome (BMI > 17.5 and return of menstruation).

2 N participants not completing therapy for any reason Show forest plot

1

13

Risk Ratio (M‐H, Random, 95% CI)

0.21 [0.03, 1.43]

Analysis 7.2

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 2 N participants not completing therapy for any reason.

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 2 N participants not completing therapy for any reason.

Open in table viewer
Comparison 8. Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment Show forest plot

1

16

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.02, 7.14]

Analysis 8.1

Comparison 8 Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy, Outcome 1 N participants not completing treatment.

Comparison 8 Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy, Outcome 1 N participants not completing treatment.

Open in table viewer
Comparison 9. CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N of participants not completing treatment Show forest plot

1

16

Risk Ratio (M‐H, Random, 95% CI)

0.2 [0.01, 3.61]

Analysis 9.1

Comparison 9 CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999), Outcome 1 N of participants not completing treatment.

Comparison 9 CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999), Outcome 1 N of participants not completing treatment.

Open in table viewer
Comparison 10. CBT versus IPT (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome ‐ number rated 3 or 4 Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.54, 1.06]

Analysis 10.1

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

2 BMI Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.62, 0.62]

Analysis 10.2

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 2 BMI.

3 EDE restraint Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐1.38, ‐0.09]

Analysis 10.3

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 3 EDE restraint.

4 Global ssessment of function (GAF‐DSM‐IV) Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

0.25 [‐0.38, 0.87]

Analysis 10.4

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 4 Global ssessment of function (GAF‐DSM‐IV).

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 4 Global ssessment of function (GAF‐DSM‐IV).

5 Hamilton depression rating scale (HDRS) Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.39 [‐1.02, 0.24]

Analysis 10.5

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 5 Hamilton depression rating scale (HDRS).

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 5 Hamilton depression rating scale (HDRS).

Open in table viewer
Comparison 11. CBT versus nonspecific clinician support (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome‐ number rated 3 or 4 (poor) Show forest plot

1

35

Risk Ratio (M‐H, Random, 95% CI)

1.56 [0.83, 2.95]

Analysis 11.1

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome‐ number rated 3 or 4 (poor).

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome‐ number rated 3 or 4 (poor).

2 BMI Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.34 [‐1.01, 0.33]

Analysis 11.2

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

3 EDE restraint Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

0.40 [‐0.27, 1.07]

Analysis 11.3

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

4 GAF Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.63 [‐1.31, 0.06]

Analysis 11.4

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

5 HDRS Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.65, 0.68]

Analysis 11.5

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Open in table viewer
Comparison 12. IPT versus nonspecific clinician support (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome ‐ number rated 3 or 4 Show forest plot

1

37

Risk Ratio (M‐H, Random, 95% CI)

2.07 [1.17, 3.67]

Analysis 12.1

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

2 BMI Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.91, 0.40]

Analysis 12.2

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

3 EDE restraint Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

1.17 [0.46, 1.88]

Analysis 12.3

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

4 GAF Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.89 [‐1.57, ‐0.20]

Analysis 12.4

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

5 HDRS Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

0.42 [‐0.24, 1.08]

Analysis 12.5

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end)..
Figuras y tablas -
Analysis 1.2

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end)..

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 3 N participants not completing treatment for any reason.
Figuras y tablas -
Analysis 1.3

Comparison 1 CAT versus individual focal psychotherapy (FPT: Dare et al., 2001)., Outcome 3 N participants not completing treatment for any reason.

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved"..
Figuras y tablas -
Analysis 2.1

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved"..

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the treatment for any reason.
Figuras y tablas -
Analysis 2.2

Comparison 2 FPT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the treatment for any reason.

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months.
Figuras y tablas -
Analysis 3.1

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months.

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the trial for any reason.
Figuras y tablas -
Analysis 3.2

Comparison 3 CAT versus treatment as usual (Dare et al., 2001), Outcome 2 N participants not completing the trial for any reason.

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 1 N participants not completing treatment for any reason.
Figuras y tablas -
Analysis 4.1

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 1 N participants not completing treatment for any reason.

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 2 Mean BMI at end of treatment.
Figuras y tablas -
Analysis 4.2

Comparison 4 Dietary advice versus cognitive therapy (Serfaty et al., 1999), Outcome 2 Mean BMI at end of treatment.

Comparison 5 Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control, Outcome 1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities..
Figuras y tablas -
Analysis 5.1

Comparison 5 Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control, Outcome 1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities..

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 1 N participants not completing treatment for any reason.
Figuras y tablas -
Analysis 6.1

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 1 N participants not completing treatment for any reason.

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up..
Figuras y tablas -
Analysis 6.2

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up..

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 3 Mean BMI at 12 months follow‐up.
Figuras y tablas -
Analysis 6.3

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 3 Mean BMI at 12 months follow‐up.

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 4 Average Morgan & Russell scores at 12 months follow‐up.
Figuras y tablas -
Analysis 6.4

Comparison 6 Educational psychotherapy versus CAT (Treasure et al., 1995), Outcome 4 Average Morgan & Russell scores at 12 months follow‐up.

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 1 N participants not having a good outcome (BMI > 17.5 and return of menstruation).
Figuras y tablas -
Analysis 7.1

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 1 N participants not having a good outcome (BMI > 17.5 and return of menstruation).

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 2 N participants not completing therapy for any reason.
Figuras y tablas -
Analysis 7.2

Comparison 7 Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999), Outcome 2 N participants not completing therapy for any reason.

Comparison 8 Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy, Outcome 1 N participants not completing treatment.
Figuras y tablas -
Analysis 8.1

Comparison 8 Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy, Outcome 1 N participants not completing treatment.

Comparison 9 CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999), Outcome 1 N of participants not completing treatment.
Figuras y tablas -
Analysis 9.1

Comparison 9 CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999), Outcome 1 N of participants not completing treatment.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.
Figuras y tablas -
Analysis 10.1

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 2 BMI.
Figuras y tablas -
Analysis 10.2

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 3 EDE restraint.
Figuras y tablas -
Analysis 10.3

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 4 Global ssessment of function (GAF‐DSM‐IV).
Figuras y tablas -
Analysis 10.4

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 4 Global ssessment of function (GAF‐DSM‐IV).

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 5 Hamilton depression rating scale (HDRS).
Figuras y tablas -
Analysis 10.5

Comparison 10 CBT versus IPT (McIntosh et al., 2005), Outcome 5 Hamilton depression rating scale (HDRS).

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome‐ number rated 3 or 4 (poor).
Figuras y tablas -
Analysis 11.1

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome‐ number rated 3 or 4 (poor).

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.
Figuras y tablas -
Analysis 11.2

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.
Figuras y tablas -
Analysis 11.3

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.
Figuras y tablas -
Analysis 11.4

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.
Figuras y tablas -
Analysis 11.5

Comparison 11 CBT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.
Figuras y tablas -
Analysis 12.1

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 1 Global treatment outcome ‐ number rated 3 or 4.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.
Figuras y tablas -
Analysis 12.2

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 2 BMI.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.
Figuras y tablas -
Analysis 12.3

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 3 EDE restraint.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.
Figuras y tablas -
Analysis 12.4

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 4 GAF.

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.
Figuras y tablas -
Analysis 12.5

Comparison 12 IPT versus nonspecific clinician support (McIntosh et al., 2005), Outcome 5 HDRS.

Table 1. DSM‐IV criteria for anorexia nervosa

DSM‐IV criteria

a.Refusal to maintain body weight at or above a minimally normal weight for age and height, (eg. weight loss leading to maintenance of body weight less than 85% of that expected; or failure to make expected weight gain during period of growth, leading to body weight less than 85% below that expected)

b. Intense fear of gaining weight or becoming fat, even though underweight

c. Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self‐evaluation, or denial of the seriousness of the current low body weight

d. In post‐menarcheal females, amenorrhoea, ie. absence of at least three consecutive menstrual cycles (a woman is considered to have amenorrhoea if her periods occur only following hormone, eg. oestrogen, administration).
Anorexia nervosa may be further defined as meeting criteria for either the restrictive type (during the current episode of anorexia nervosa, the person has not regularly engaged in binge‐eating or purging behaviour, ie. self‐induced vomiting or the misuse of laxatives, diuretics, or enemas), or the binge‐eating/purging type (during the current episode of anorexia nervosa, the person has regularly engaged in binge‐eating or purging behaviour, ie. self‐induced vomiting or the misuse of laxatives, diuretics or enemas).

Figuras y tablas -
Table 1. DSM‐IV criteria for anorexia nervosa
Table 2. Quality Rating Scale criteria

QRS criteria

Quality Rating Scale (QRS) criteria

1. Objectives and specification main outcomes a priori
0=unclear
1=objectives clear but main outcomes not specified a priori
2=objectives clear with a priori specification

2. Sample size per group
0=<50
1=50‐100
2=>100

3. Planned duration of trial including follow‐up
0=<3 months
1=>3 TO <6 months
2=> 6 months

Also recorded are the duration of treatment (weeks) and duration of follow‐up (months)

4. Power calculation
0=not reported
1=mentioned without details
2=details provided

5. Method of allocation
0=not randomised and likely to be biased
1=partial or quasi randomised with some bias possible
2=randomised

6. The concealment of randomization:
2. indicates adequate concealment
1. indicates uncertainty about whether allocation was adequately concealed ‐ partial concealment only
0. indicates the allocation was definitely not adequately concealed

NB. This refers to protecting details on how the allocation code from those involved in patient recruitment. This may be achieved by having allocation done by a central independent body, or protection of code by e.g. sealed opaque envelopes.

7. Clear description of treatment (including drug dosages and adjunctive treatment)
0=main treatments not clearly described
1=inadequate details of main or adjunctive treatments
2=full details

8. Blinding – the quality of blinding would be rated according to the following scale:
3. Done and integrity tested
2. Blinding of outcome assessor and the participant but no test of blinding.
1. Blinding of outcome assessor or participant only (single‐blind).
0. Blinding not done

NB Test of integrity of blind is normally done by asking participants to guess their allocated group. Results can be compared to those which would be expected by chance.

9. Source of subjects described and representative sample recruitment that meets the aims of the trial.
0 = source of subjects not described
1 = source of subjects described but is unrepresentative
2 = source of subjects described plus representative sample taken

10. Use of diagnostic criteria (or clear specification of inclusion criteria)
0 = None
1 = Diagnostic criteria or clear inclusion criteria
2 = Diagnostic criteria + specification of severity

11. Record of exclusion criteria and number of exclusions and refusals reported
0 = Criteria and number not reported
1 = criteria or number of exclusions & refusals not reported
2 = criteria and number of exclusions and refusal reported

12. Description of sample demographics
0 = Little/no info (only age/sex)
1 = Basic details (e.g. marital status/ethnicity)
2 = Full description (e.g. socio‐economic status/clinical history)

13. Assessment of compliance with experimental treatments (including attendance for therapy)
0 = Not assessed
1 = Assessed for some experimental treatments
2 = Assessed for all experimental treatments

14. Details on side‐effects
0 = Inadequate details
1 = Recorded by group but details inadequate
2 = Full side effect profiles by group

15. Record of number and reasons for withdrawal by group
0 = No info on withdrawals by group
1 = Withdrawals by group reported without reason
2 = Withdrawals and reason by group

16. Outcome measures described clearly or use of validated instruments
0 = outcomes not described clearly
1= some outcomes not clearly described
2= outcomes described or valid & reliable instruments used

17. Information on comparability and adjustment for differences in analysis
0= no info on comparability
0.5= some info on comparability without appropriate adjustment
1= some info on comparability with appropriate adjustment
2= sufficient comparability info with appropriate adjustment

18. Inclusion of withdrawals in analysis
0 = Not included or not reported
1 = Withdrawals included in analysis by estimation of outcome
2 = Withdrawals followed up and included in analysis

19. Presentation of results with inclusion of data for re‐analysis of main outcomes
0 = Inadequate presentation
1= Adequate
2 = Comprehensive

20. Appropriate statistical analysis (including correction for multiple tests where applicable)
0 = Inappropriate
1 = Mainly appropriate
2 = Appropriate and comprehensive

21. Conclusions justified
0 = No
1 = Partially
2 = Yes

22. Declaration of interests (e.g. source of funding)
0 = No
1 = Yes

Figuras y tablas -
Table 2. Quality Rating Scale criteria
Comparison 1. CAT versus individual focal psychotherapy (FPT: Dare et al., 2001).

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

2 N not meeting Morgan & Russell "recovered" or "significantly improved" outcome criteria at 12 months (Rx end). Show forest plot

1

43

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.73, 1.62]

3 N participants not completing treatment for any reason Show forest plot

1

43

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.47, 1.93]

Figuras y tablas -
Comparison 1. CAT versus individual focal psychotherapy (FPT: Dare et al., 2001).
Comparison 2. FPT versus treatment as usual (Dare et al., 2001)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N of participants not meeting Morgan and Russell's criteria for "recovered" or "significantly improved". Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.70 [0.51, 0.97]

2 N participants not completing the treatment for any reason Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.72 [0.23, 2.31]

Figuras y tablas -
Comparison 2. FPT versus treatment as usual (Dare et al., 2001)
Comparison 3. CAT versus treatment as usual (Dare et al., 2001)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants in Morgan & Russell in 'poor' or 'intermediate' categories at 12‐months Show forest plot

1

41

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.58, 1.01]

2 N participants not completing the trial for any reason Show forest plot

1

41

Risk Ratio (M‐H, Random, 95% CI)

1.30 [0.56, 2.97]

Figuras y tablas -
Comparison 3. CAT versus treatment as usual (Dare et al., 2001)
Comparison 4. Dietary advice versus cognitive therapy (Serfaty et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment for any reason Show forest plot

1

35

Risk Ratio (M‐H, Random, 95% CI)

0.10 [0.03, 0.33]

2 Mean BMI at end of treatment Show forest plot

1

35

Std. Mean Difference (IV, Random, 95% CI)

0.71 [‐0.05, 1.46]

Figuras y tablas -
Comparison 4. Dietary advice versus cognitive therapy (Serfaty et al., 1999)
Comparison 5. Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Remission defined by normal: body weight, psychology, test results, eating behaviour & social activities. Show forest plot

1

19

Risk Ratio (M‐H, Random, 95% CI)

15.75 [1.06, 234.87]

Figuras y tablas -
Comparison 5. Karolinski Institute (Bergh et al., 2002) outpatient treatment versus wait‐list control
Comparison 6. Educational psychotherapy versus CAT (Treasure et al., 1995)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment for any reason Show forest plot

1

30

Risk Ratio (M‐H, Random, 95% CI)

0.88 [0.53, 1.45]

2 Morgan and Russell 'poor or intermediate' outcomes at one year follow‐up. Show forest plot

1

30

Risk Ratio (M‐H, Random, 95% CI)

1.20 [0.69, 2.11]

3 Mean BMI at 12 months follow‐up Show forest plot

1

30

Std. Mean Difference (IV, Random, 95% CI)

‐0.41 [‐1.13, 0.32]

4 Average Morgan & Russell scores at 12 months follow‐up Show forest plot

1

30

Std. Mean Difference (IV, Random, 95% CI)

‐0.32 [‐1.04, 0.40]

Figuras y tablas -
Comparison 6. Educational psychotherapy versus CAT (Treasure et al., 1995)
Comparison 7. Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not having a good outcome (BMI > 17.5 and return of menstruation) Show forest plot

1

13

Risk Ratio (M‐H, Random, 95% CI)

0.34 [0.12, 0.96]

2 N participants not completing therapy for any reason Show forest plot

1

13

Risk Ratio (M‐H, Random, 95% CI)

0.21 [0.03, 1.43]

Figuras y tablas -
Comparison 7. Self‐psychology versus cognitive orientation therapy (both with nutritional counselling; Bachar et al., 1999)
Comparison 8. Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N participants not completing treatment Show forest plot

1

16

Risk Ratio (M‐H, Random, 95% CI)

0.33 [0.02, 7.14]

Figuras y tablas -
Comparison 8. Cognitive‐behavioural therapy (Channon et al., 1989 & Garner & Bemis, 1982, 1985) versus Behaviour therapy
Comparison 9. CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 N of participants not completing treatment Show forest plot

1

16

Risk Ratio (M‐H, Random, 95% CI)

0.2 [0.01, 3.61]

Figuras y tablas -
Comparison 9. CBT versus eclectic specialist therapy ("treatment as usual"; Channon et al., 1999)
Comparison 10. CBT versus IPT (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome ‐ number rated 3 or 4 Show forest plot

1

40

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.54, 1.06]

2 BMI Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

0.0 [‐0.62, 0.62]

3 EDE restraint Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.74 [‐1.38, ‐0.09]

4 Global ssessment of function (GAF‐DSM‐IV) Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

0.25 [‐0.38, 0.87]

5 Hamilton depression rating scale (HDRS) Show forest plot

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.39 [‐1.02, 0.24]

Figuras y tablas -
Comparison 10. CBT versus IPT (McIntosh et al., 2005)
Comparison 11. CBT versus nonspecific clinician support (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome‐ number rated 3 or 4 (poor) Show forest plot

1

35

Risk Ratio (M‐H, Random, 95% CI)

1.56 [0.83, 2.95]

2 BMI Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.34 [‐1.01, 0.33]

3 EDE restraint Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

0.40 [‐0.27, 1.07]

4 GAF Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.63 [‐1.31, 0.06]

5 HDRS Show forest plot

1

35

Std. Mean Difference (IV, Fixed, 95% CI)

0.01 [‐0.65, 0.68]

Figuras y tablas -
Comparison 11. CBT versus nonspecific clinician support (McIntosh et al., 2005)
Comparison 12. IPT versus nonspecific clinician support (McIntosh et al., 2005)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global treatment outcome ‐ number rated 3 or 4 Show forest plot

1

37

Risk Ratio (M‐H, Random, 95% CI)

2.07 [1.17, 3.67]

2 BMI Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.25 [‐0.91, 0.40]

3 EDE restraint Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

1.17 [0.46, 1.88]

4 GAF Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.89 [‐1.57, ‐0.20]

5 HDRS Show forest plot

1

37

Std. Mean Difference (IV, Fixed, 95% CI)

0.42 [‐0.24, 1.08]

Figuras y tablas -
Comparison 12. IPT versus nonspecific clinician support (McIntosh et al., 2005)